Amgen reports that a drug for Sjögren’s disease has met the primary endpoint in a Phase 3 trial of approximately 621 people. At the time of its announcement, Amgen said no FDA-approved medicine treated the disease itself. But the announcement leaves out the number patients and doctors most need—the size of the benefit over placebo.
Amgen’s September 22 topline release says dazodalibep produced a statistically significant and clinically meaningful improvement in systemic disease activity at week 48. It does not report the treatment-group change, the placebo-group change, their difference, confidence interval or p-value. Until full data appear, “positive” describes the trial’s direction—not how much better a patient is likely to feel or function.
Sjögren’s is more than dryness
Sjögren’s is an autoimmune disease in which immune activity can damage moisture-producing glands and affect organs throughout the body. Dry eyes and mouth are its most familiar features, but people can also experience fatigue, pain, arthritis, neuropathy and organ involvement. The disease varies widely, which makes one endpoint unlikely to capture every outcome that matters.
OASIZ 301 enrolled adults with an ESSDAI score of at least five. ESSDAI—the EULAR Sjögren’s Syndrome Disease Activity Index—combines activity across organ systems into a clinician-scored measure. The randomized, double-blind study compared dazodalibep with placebo for 48 weeks. Its primary endpoint was the change in ESSDAI from baseline; secondary endpoints included dryness, fatigue, tender and swollen joints, and the proportion of participants whose score fell by at least five points.
A trial can be statistically positive without telling us whether the average improvement is large, modest or concentrated in one group. “Clinically meaningful” is stronger language, but it still needs the actual difference, uncertainty and secondary outcomes. Those numbers determine whether a result changes care rather than merely clearing a statistical threshold.
Amgen says ESSDAI improvement appeared by week four and persisted through week 48. That temporal pattern is encouraging, but the release does not show the curve or say how many participants achieved the five-point response. Detailed results are promised for a future medical meeting.
The drug blocks an immune conversation
Dazodalibep is a fusion protein designed to block CD40 ligand, or CD40L. CD40L on activated T cells binds CD40 on B cells and other antigen-presenting cells, helping coordinate immune activation, antibody production and inflammatory signaling. Interrupting that handshake aims to turn down several parts of the autoimmune response without broadly eliminating immune cells.
The mechanism already has human evidence. In a peer-reviewed Phase 2 trial published in Nature Medicine, 74 participants with moderate-to-severe systemic activity had an adjusted mean ESSDAI change of −6.3 points with dazodalibep versus −4.1 with placebo at day 169, a 2.2-point difference. A separate 109-person population with high symptom burden and limited organ involvement also met its patient-reported primary endpoint.
Phase 2 established a plausible signal, not a guarantee that a larger and longer trial would reproduce it. OASIZ 301 is therefore meaningful precisely because it tested the systemic-disease population at Phase 3 scale. The missing effect-size data matter for the same reason: a larger study can make a small difference statistically convincing.
Safety needs denominators too
Amgen reports that the most common adverse events occurring in at least 5% of participants and more often with dazodalibep were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions. It says they were generally mild or moderate, discontinuations were low and balanced, and no imbalance appeared in thromboembolic events or opportunistic infections.
That is useful, but no event rates or exposure-adjusted numbers are given. CD40L is an important immune signal, so infection and longer-term immune effects remain central questions. Older anti-CD40L antibody programs also raised concern about clotting; dazodalibep’s non-antibody fusion design was developed in part to avoid the platelet cross-linking implicated in that problem. One 48-week topline summary cannot establish long-term safety.
The next result could broaden the story. OASIZ 303 studies people whose dryness, fatigue or pain is high even though systemic organ activity is lower, and Amgen expects it to complete in the fourth quarter of 2026. That population may better reflect many patients’ daily burden, while OASIZ 301 asks the clearer organ-activity question.
For now, the accurate conclusion is narrower than a breakthrough headline and stronger than “just a press release.” A randomized Phase 3 trial met its primary goal, supporting the CD40L pathway as a serious treatment target. Whether dazodalibep delivers a worthwhile improvement will be answerable only when Amgen releases the missing numbers—and when regulators can inspect the full dataset rather than its topline description.
Keep exploring
- These cell clusters give blood a new route — how a laboratory model can answer a mechanism question without becoming a therapy.
- These mice carry human cortical tissue—not human brains — a guide to reading an ambitious biological model at the right scale.
- Semaglutide extended lifespan in mice. What did it prove? — why the evidence stage changes the claim.
AI-assisted. Sources checked.
